Join the club for FREE to access the whole archive and other member benefits.

Young blood as a key to living longer


Key points from article :

A new startup Elevian got 5.5$ from investors for “death disruption” scene.

Drugs based on GDF11 could treat Alzheimer’s, coronary heart disease, age-related muscle dysfunction.

GDF11 injected on its own, made old mice stronger, increased blood flow to their brains.

In 2016, Ambrosia company launched the first human trial of young plasma transfusions.

Young blood could improve memory and learning in older rodents.

Even a short course of weekly plasma infusions could improve some of the Alzheimer’s symptoms.

The study was published in Science journal.

GDF11 is a protein in the blood, which can stimulate cell growth and repair

Mentioned in this article:

Click on resource name for more details.


Biotechnology company focused on treating neurodegenerative and other age-related diseases


Offers young blood plasma transfers after running a trial in 2016-18

Amy Wagers

Senior Investigator and Co-chair at Harvard Department of Stem Cell and Regenerative Biology


Young blood medicine maker for body rejuvenation.

Harvard University

Private Ivy League research university in Massachusetts

Jesse Karmazin

CEO of the blood transfusion company Ambrosia.

Science Magazine

Academic journal of the American Association for the Advancement of Science (AAAS) and one of the world's top academic journals

Stanford University

Private research university, one of the world's leading research and teaching institutions

Tony Wyss-Coray

Professor at Stanford University School of Medicine